WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H581769
CAS#: 24928-26-5
Description: N,N-Dipropyldecanamide is a biochemical.
Hodoodo Cat#: H581769
Name: N,N-Dipropyldecanamide
CAS#: 24928-26-5
Chemical Formula: C16H33NO
Exact Mass: 255.26
Molecular Weight: 255.446
Elemental Analysis: C, 75.23; H, 13.02; N, 5.48; O, 6.26
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: N,N-Dipropyldecanamide; Decanamide, N,N-dipropyl-.
IUPAC/Chemical Name: N,N-dipropyldecanamide
InChi Key: XRGQSRGEPOBQIF-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H33NO/c1-4-7-8-9-10-11-12-13-16(18)17(14-5-2)15-6-3/h4-15H2,1-3H3
SMILES Code: O=C(N(CCC)CCC)CCCCCCCCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 255.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pedersen DS, Bélanger P, Frykman M, Andreasen K, Goudreault D, Pedersen H, Hindersson P, Breindahl T. Ethylene glycol: Evidence of glucuronidation in vivo shown by analysis of clinical toxicology samples. Drug Test Anal. 2019 Mar 7. doi: 10.1002/dta.2584. [Epub ahead of print] PubMed PMID: 30845374.
2: Duckworth AD, McQueen MM, Tuck CE, Tobias JH, Wilkinson JM, Biant LC, Pulford EC, Aldridge S, Edwards C, Roberts CP, Ramachandran M, McAndrew AR, Cheng KC, Johnston P, Shah NH, Mathew P, Harvie J, Hanusch BC, Harkess R, Rodriguez A, Murray GD, Ralston SH. Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial. J Bone Miner Res. 2019 Mar 7. doi: 10.1002/jbmr.3679. [Epub ahead of print] PubMed PMID: 30845365.
3: Rodrigues RC, Hasui É, Assis JC, Castro Pena JC, Muylaert RL, Tonetti VR, Martello F, Regolin AL, Vernaschi Vieira da Costa T, Pichorim M, Carrano E, Lopes LE, de Vasconcelos MF, Fontana CS, Langeloh Roos A, Gonçalves F, Banks-Leite C, Cavarzere V, Efe MA, Alves MAS, Uezu A, Metzger JP, de Tarso Zuquim Antas P, de Barros Ferraz KMPM, Calsavara LC, Bispo AA, Araujo HFP, Duca C, Piratelli AJ, Naka LN, Dias RA, Gatto CAFR, Villegas Vallejos MA, Dos Reis Menezes G, Bugoni L, Rajão H, Zocche JJ, Willrich G, da Silva ES, Manica LT, de Camargo Guaraldo A, Althmann G, Pereira Serafini P, Francisco MR, Lugarini C, Machado CG, Marques-Santos F, Bobato R, de Souza EA, Donatelli RJ, Ferreira CD, Morante-Filho JC, Paes-Macarrão ND, Macarrão A, Lima MR, Jacoboski LI, Candia-Gallardo C, Bejarano Alegre V, Jahn AE, de Camargo Barbosa KV, Cestari C, da Silva JN, Da Silveira NS, Crestani ACV, Petronetto AP, Bovo AAA, Viana AD, Araujo AC, Dos Santos AH, do Amaral ACA, Ferreira A, Vieira-Filho AH, Ribeiro BC, Missagia CCC, Bosenbecker C, Medolago CAB, Espínola CRR, Faxina C, Nunes CEC, Prates C, da Luz DTA, Moreno DJ, Mariz D, Faria D, Meyer D, Doná EA, Alexandrino ER, Fischer E, Girardi F, Giese FB, Santos Shibuya FL, Faria FA, de Farias FB, de Lima Favaro F, Ferneda Freitas FJ, Chaves FG, Las-Casas FMG, Rosa GLM, De La Torre GM, Bochio GM, Bonetti GE, Kohler G, Toledo-Lima GS, Plucenio GP, Menezes Í, Torres IMD, Provinciato ICC, Viana IR, Roper JJ, Persegona JE, Barcik JJ, Martins-Silva J, Just JPG, Tavares-Damasceno JP, de Almeida Ferreira JR, Rosoni JRR, Falcon JET, Schaedler LM, Mathias LB, Deconto LR, da Cruz Rodrigues L, Meyer MAP, Repenning M, Melo MA, de Carvalho MAS, Rodrigues M, Nunes MFC, Ogrzewalska MH, Gonçalves ML, Vecchi MB, Bettio M, Noronha da Matta Baptista M, Arantes MS, Ruiz NL, de Andrade PGB, Ribeiro PHL, Galetti Junior PM, Macario P, de Oliveira Fratoni R, Meurer R, Saint-Clair RS, Romagna RS, Lacerda RCA, Cerboncini RAS, Lyra RB, Lau R, Rodrigues RC, Faria RR, Laps RR, Althoff SL, de Jesus S, Namba S, Braga TV, Molin T, Câmara TPF, Enedino TR, Wischhoff U, de Oliveira VC, Leandro-Silva V, Araújo-Lima V, de Oliveira Lunardi V, de Gusmão RF, de Souza Correia JM, Gaspar LP, Fonseca RCB, Pires Neto PAF, de Aquino ACMM, de Camargo BB, Cezila BA, Marques Costa L, Paolino RM, Kanda CZ, Monteiro ECS, Oshima JEF, Alves-Eigenheer M, Pizo MA, Silveira LF, Galetti M, Ribeiro MC. ATLANTIC BIRD TRAITS: a dataset of bird morphological traits from the Atlantic forests of South America. Ecology. 2019 Mar 7:e02647. doi: 10.1002/ecy.2647. [Epub ahead of print] PubMed PMID: 30845354.
4: Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharmacol. 2019 Mar 7. doi: 10.1111/bcp.13915. [Epub ahead of print] PubMed PMID: 30845347.
5: Floyd CN, Lidder S, Hunt J, Omar SA, McNeill K, Webb AJ. Acute interaction between oral glucose (75 g as Lucozade) and inorganic nitrate: decreased insulin clearance, but lack of blood pressure-lowering. Br J Clin Pharmacol. 2019 Mar 7. doi: 10.1111/bcp.13913. [Epub ahead of print] PubMed PMID: 30845346.
6: Tack B, Phoba MF, Van Puyvelde S, Kalonji LM, Hardy L, Barbé B, Van der Sande MAB, Monsieurs E, Deborggraeve S, Lunguya O, Jacobs J. Salmonella Typhi From Blood Cultures in the Democratic Republic of the Congo: A 10-Year Surveillance. Clin Infect Dis. 2019 Mar 7;68(Supplement_2):S130-S137. doi: 10.1093/cid/ciy1116. PubMed PMID: 30845337.
7: Leighton SP, Krishnadas R, Chung K, Blair A, Brown S, Clark S, Sowerbutts K, Schwannauer M, Cavanagh J, Gumley AI. Predicting one-year outcome in first episode psychosis using machine learning. PLoS One. 2019 Mar 7;14(3):e0212846. doi: 10.1371/journal.pone.0212846. eCollection 2019. PubMed PMID: 30845268.
8: Schärer C, Lehmann T, Naundorf F, Taube W, Hübner K. The faster, the better? Relationships between run-up speed, the degree of difficulty (D-score), height and length of flight on vault in artistic gymnastics. PLoS One. 2019 Mar 7;14(3):e0213310. doi: 10.1371/journal.pone.0213310. eCollection 2019. PubMed PMID: 30845256.
9: Radel R, Gruet M, Barzykowski K. Testing the ego-depletion effect in optimized conditions. PLoS One. 2019 Mar 7;14(3):e0213026. doi: 10.1371/journal.pone.0213026. eCollection 2019. PubMed PMID: 30845243.
10: Marinho CL, Maioli MCP, Amaral JLMD, Lopes AJ, Melo PL. Respiratory resistance and reactance in adults with sickle cell anemia: Part 2-Fractional-order modeling and a clinical decision support system for the diagnosis of respiratory disorders. PLoS One. 2019 Mar 7;14(3):e0213257. doi: 10.1371/journal.pone.0213257. eCollection 2019. PubMed PMID: 30845242.
11: Veyssiere M, Perea J, Michou L, Boland A, Caloustian C, Olaso R, Deleuze JF, Cornelis F, Petit-Teixeira E, Chaudru V. A novel nonsense variant in SUPT20H gene associated with Rheumatoid Arthritis identified by Whole Exome Sequencing of multiplex families. PLoS One. 2019 Mar 7;14(3):e0213387. doi: 10.1371/journal.pone.0213387. eCollection 2019. PubMed PMID: 30845214.
12: Servaes S, Glorie D, Stroobants S, Staelens S. Neuroreceptor kinetics in rats repeatedly exposed to quinpirole as a model for OCD. PLoS One. 2019 Mar 7;14(3):e0213313. doi: 10.1371/journal.pone.0213313. eCollection 2019. PubMed PMID: 30845202.
13: Kim HM, Choi EK, Park CS, Cha MJ, Lee SY, Kwon JM, Oh S. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS One. 2019 Mar 7;14(3):e0211766. doi: 10.1371/journal.pone.0211766. eCollection 2019. PubMed PMID: 30845196.
14: Baarda BI, Zielke RA, Le Van A, Jerse AE, Sikora AE. Neisseria gonorrhoeae MlaA influences gonococcal virulence and membrane vesicle production. PLoS Pathog. 2019 Mar 7;15(3):e1007385. doi: 10.1371/journal.ppat.1007385. [Epub ahead of print] PubMed PMID: 30845186.
15: Sinpoo C, Disayathanoowat T, Williams PH, Chantawannakul P. Prevalence of infection by the microsporidian Nosema spp. in native bumblebees (Bombus spp.) in northern Thailand. PLoS One. 2019 Mar 7;14(3):e0213171. doi: 10.1371/journal.pone.0213171. eCollection 2019. PubMed PMID: 30845178.
16: Daun F, Kibele A. Different strength declines in leg primary movers versus stabilizers across age-Implications for the risk of falls in older adults? PLoS One. 2019 Mar 7;14(3):e0213361. doi: 10.1371/journal.pone.0213361. eCollection 2019. PubMed PMID: 30845168.
17: Broadrup RL, Mayack C, Schick SJ, Eppley EJ, White HK, Macherone A. Honey bee (Apis mellifera) exposomes and dysregulated metabolic pathways associated with Nosema ceranae infection. PLoS One. 2019 Mar 7;14(3):e0213249. doi: 10.1371/journal.pone.0213249. eCollection 2019. PubMed PMID: 30845162.
18: Zendle D, Cairns P. Loot boxes are again linked to problem gambling: Results of a replication study. PLoS One. 2019 Mar 7;14(3):e0213194. doi: 10.1371/journal.pone.0213194. eCollection 2019. PubMed PMID: 30845155.
19: Fujiya Y, Hayakawa K, Gu Y, Yamamoto K, Mawatari M, Kutsuna S, Takeshita N, Kato Y, Kanagawa S, Ohmagari N. Age-related differences in clinical characteristics of invasive group G streptococcal infection: Comparison with group A and group B streptococcal infections. PLoS One. 2019 Mar 7;14(3):e0211786. doi: 10.1371/journal.pone.0211786. eCollection 2019. PubMed PMID: 30845149.
20: Blakey AG, Main S. Nothing short of universal healthcare coverage, fully funded and without charge both in primary and hospital care is good enough for New Zealand. N Z Med J. 2019 Mar 8;132(1491):107-108. PubMed PMID: 30845138.
